chILD

Childhood ILD Week

lam

Welcome Message

Welcome to this week’s focused feature with our Public Advisory Roundtable (PAR) partner the Children’s Interstitial Lung Disease (chILD) Foundation.  Tremendous advances have been made in the past decade in characterizing the diffuse parenchymal lung diseases of infants and children.  New disorders have been described and molecular screening for some of these disorders is now available. An overview of these diseases in children is included in this weeks’ educational summary.

Although the timely diagnosis and therapy of these rare lung diseases is important, equally important is the access to family educational resources, contacts with experts in the field and knowledge of available research studies that are facilitated by the chILD Foundation.  An annual conference is attended by affected families and a scientific community interested in advancing cures for these lung diseases. Another feature highlighted at the chILD Foundation is a listing of interested physicians who know these disorders and have access to a newly developed Pediatric Rare Diffuse Lung Disease registry. A research grants program that partnered with the ATS Foundation has named Laertis Ikonomou, PhD, assistant professor of medicine at Boston University School of Medicine, as the recipient of this year’s grant to study genetic mutations in children with interstitial lung disease.

In summary, the ATS is proud of the collaborations made with disease specific foundations such as the chILD Foundation in support of their mission to provide support, education and hope to families affected with a pediatric interstitial lung disease and to advocate and raise funds for scientific research.

strange

Charlie Strange, MD
Chair, 
ATS Assembly on Clinical Problems
Member, ATS Board of Directors

 porta

Greg Porta
Founder,
chILD Foundation
Member, ATS Public Advisory Roundtable

ATS ILD Partner

image

The chILD foundation was established in 2004 to provide support, education and hope to families affected with a pediatric interstitial lung disease and to advocate and raise funds for scientific research.

Disclaimer: "The ATS Lung Disease Week Web site is designed for educational purposes only. You should not rely on this information as a substitute for personal medical attention, a diagnosis from a physician, or direct medical care.  If you are concerned about your health or that of a family member, please consult your family's healthcare provider immediately. Do not wait for a response from our members, staff or partners."